Half-life
Very short plasma; intranasal CNS absorption studied
Evidence Level
Moderate Evidence
Mechanism of Action
Modulates GABAergic, serotonergic, and dopaminergic systems. Increases BDNF expression. Tryptophan metabolism modulation may explain anxiolytic and mood-stabilizing effects.
Published Research Ranges & Study Context
Studies have administered: 250–3000mcg/day intranasal in published Russian clinical research
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Russian clinical trials demonstrate anxiety reduction comparable to benzodiazepines without dependence or sedation. Cognitive enhancement with simultaneous anxiolysis is notable finding.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
Non-sedating, non-dependent; nasal irritation; generally very well-tolerated in studies
Available Configurations (SKU Reference)
SK5
SK11
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Selank — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.